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   Surgery remains the cornerstone for the curative treatment of non-small cell lung cancer (NSCLC). 
Long-term survival depends on different prognostic factors including the tumour extent (the T and N 
stage) and the quality of the surgical resection (complete vs. incomplete resection, the type 
of mediastinal exploration). Nevertheless, only one-third of all operated patients will be metastases 
alive 5 years after the surgical resection. Failures are due to a loco-regional relapse, distant 
metastases or a second primary cancer related to the long story of tobacco abuse. The pattern 
of failure analysis should decide on the type of adjuvant treatment: a loco regional modality or a form 
of systemic treatment such as chemotherapy or immunotherapy.  
 
Adjuvant Chemotherapy 
 
   For more than four decades in many 
trials the value of adjuvant chemotherapy 
after surgery without helping to clearly 
clarify the issue has been tested. Most 
trials did not show any benefit or even had 
a negative impact; some small trials 
claimed survival benefits. The meta-
analysis conducted in the mid nineties by 
the Cambridge group included 14 trials 
comparing surgery vs. surgery plus 
chemotherapy for a total of 4357 patients 
and 7 trials evaluating the role of chemo-
therapy after surgery and postoperative 
radiotherapy for a total of 807 patients [1]. 
This metaanalysis was based on a review 
of updated data of individual patients. 
For the first group of trials without 
postoperative radiotherapy, the use of a 
long term alkylating agent (cytoxan, nitro-
sourea…) led to a 15% increase in the risk 
of death; this was reflected in an absolute 
detriment due to the chemotherapy of 4% 
at 2 years and 5% at 5 years. For eight 
more recent trials using a cisplatine-based 
chemotherapy, there was a trend in favor of 
chemotherapy with an absolute benefit at 2 
and 5 years of 3 and 5% respectively. 
Those differences did not show a statis-
tically significant difference. The same 
figures were observed for the trials where 
chemotherapy was applied after surgery 
and postoperative radiotherapy: the sur-
vival benefit was in the range of 2% at five 
years. 
   The Cambridge metaanalysis was 
the starting point for several randomized 
trials worldwide such as ANITA in France, 
ALPI in Italy and IALT worldwide. 
The main feature of those trials is that they 
use a cisplatine based chemotherapy and 
recruit thousands of patients so as to show 
a small but very important benefit due 
to the high number of patients at risk.  
   The recent American trial of Keller et al. 
compared postoperative radiotherapy 
alone with a combined chemo-radio-
therapy approach for completely resected 
stage II or IIIa disease [2,3]. The trial 
includes 488 patients. The chemotherapy 
consisted of cisplatin and etoposide 
administered for 4 cycles with the first two 
cycles given concurrently with radio-
therapy and the chest radiotherapy 
delivered 50.4 Gy in 28 daily fractions. 
No difference was observed between two 
arms. The only important prognostic factor 
was the type of mediastinal exploration: 
sampling vs. radical dissection [3]. 
Sampling dissection included a removal 
of at least one lymph node at levels 
4,7 and 10 during the right thoracotomy, 
and at levels 5 and/ or 6 and 7 during the 
left thoracotomy, whereas radical 
resection required a complete removal 
of all lymph nodes at those levels. Among 
222 patients with N2 disease, multiple
 
_____________________________________________________________________________________________________ 
Proceedings of the Conference “Advances in Radiation Oncology: Diagnosis-Treatment Planning-Clinical Outcome”, Poznań, 
April 19th – 21st, 2001. 
Van Houtte et al.: Adjuvant treatments … 
Rep. Pract. Oncol. Radiother. 6 (4) 2001  
levels of N2 were documented in 30% 
of patients with complete mediastinal 
dissection, and in 12% of patients with 
systematic sampling. In this nonrandom-
mized comparison, the mediastinal com-
plete dissection led to a survival benefit 
for patients with right side lung tumours. 
The problem of sampling vs. radical 
dissection was the subject of only one trial: 
169 patients were randomized between 
a lymph node sampling and a systematic 
mediastinal dissection [4]. There was 
no difference in the overall survival rate 
although the number of local recurrences 
was reduced after mediastinal dissection. 
Nevertheless, mediastinal dissection 
yields a better local control and survival 
for patients with pathological N1 or limited 
N2 disease: local recurrence dropped from 
44.8% after sampling to 29% after radical 
dissection [4]. 
   Another problem involved in adjuvant 
chemotherapy after surgery is the patient’s 
compliance: in the Keller trial, 69% of 232 
patients studied received all four cycles 
of chemotherapy. Toxicity and patient’s re-
fusal were the common causes for the fai-
lure in completing the programme. The ge-
neral trend favours a neoadjuvant appro-
ach even for stage I disease, but addi-
tional clinical studies are needed to con-
firm the results of the French trial [5]. 
 
Adjuvant postoperative radiotherapy 
 
   For the last four decades, postoperative 
radiotherapy has been evaluated in many 
randomized trials without a clear result 
as to its efficacy. Does the recently pu-
blished metaanalysis definitively answer 
the question of efficacy? A simplified view 
of each individual trial and the meta-
analysis will lead to the following 
conclusion: postoperative radiotherapy 
is harmful and ineffective for a completely 
resected lung cancer. Indeed, the adverse 
impact of postoperative irradiation has 
resulted in an absolute detriment of 7% 
at 2 years and 5 years. The metaanalysis 
included individual data on 2128 patients 
in nine randomized trials; of which one has 
never been published, or presented as 
an abstract (the trial conducted by 
the European Organization for Research 
and Treatment of Cancer) [6].  
   Is there any place nowadays for post-
operative irradiation after complete 
resection of a non-small cell lung cancer ? 
The above metaanalysis and the review 
of all the randomized trials, including those 
which are not embraced by the meta-
analysis require a more critical analysis 
(Table 1) [6-17]. The randomized trials 
were conducted over a period of three 
decades. The criteria for patient selection 
varied from one trial to another: from stage 
I to stage III, from squamous cell to all hi-
stology. The definition of complete res-
ction was not the same in all trials: in the 
Lung Cancer Study Group trial, complete 
resection implied that the last nodal station 
removed in the cephalic direction was free 
of tumour [13]. Furthermore, the quality 
of the surgical resection was not certainly 
the same in all trials, especiallly regarding 
the mediastinal exploration. 
 
Table 1. Trials of postoperative thoracic radiotherapy. 
 
Authors Dose Pts Radiation N° Pathology Selection Surgery Patient Survival 
Paterson 45Gy/4w 202 All Pneum. NO N+ No Diff. 
Bangma 45Gy/5w 73 All All NO N+ No Diff. 
Van Houtte 60Gy/6w 224 All All NO No Diff. 
Israel 45Gy/4.5w 392 Sq.c. All N0 N+ No Diff.* 
Debevec 30Gy/2w  74 NSC All N+ No Diff.* 
Feng 60Gy/6w 366 NSC All N+ No Diff.* 
LCSG 50Gy/5w 230 Sq.c. All N+ No Diff.* 
MRC$        40Gy/3w 308 NSC All StageII,III No Diff.* 
Laffite 45-60Gy/4-6w 163 NSC All T2N0 No Diff. 
Dautzenberg 60Gy/6w 728 NSC All Stage I-III No Diff. 
Granone 50Gy/5w 104 NSC All Stage I No Diff. 
° Lung Cancer Study Group  $ Medical Research Council 
* Those studies show a better local control in case of positive mediastinal lymph nodes  
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   The technique of postoperative radiation 
is another important issue: in the Brussels 
study, patients were treated with a Co 60 
source delivering a dose of 60 Gy [9]. 
This was at a time when dose calculation 
was not performed using a modern 
treatment-planning unit, and no CT was 
available. The Medical Research Council 
trial delivered a dose of 40 Gy in 3 weeks, 
with a posterior spinal block [14]. In the 
Dautzenberg trial, a dose of 60 Gy was 
delivered with a linear accelerator, or even 
a cobalt unit using a 4 fields technique, 
4 or 5 times per week was employed [16]. 
   Last but not least, some interesting 
observations were reported from this 
metaanalysis and the Dautzenberg trial 
[6,16]. In the analysis by stage or by nodal 
status, the adverse impact of postopera-
tive irradiation was mainly seen for stage 
I disease, and it completely disappeared 
for stage III [6]. Two explanations are 
possible: the short life expectancy of pa-
tients with stage III disease did not make 
it possible to see the detrimental effect 
of radiation or the therapeutic effect 
of radiation that would compensate for it’s 
the negative impact. The former can easily 
be refuted: one of the main causes of late 
toxicity induced by postoperative irradia-
tion is related to lung damage; since 
pneumonia and lung fibrosis occur within 
the first year of observation. Dautzenberg 
et al. reported non-cancer related deaths 
corresponding to the daily radiation dose: 
7% for the control group, 16% for less than 
2 Gy, 18% for 2 Gy and 26% for more than 
2 Gy. [16]. In that trial, a dose of 60 Gy 
was delivered over six weeks from a linear 
accelerator or a cobalt 60 unit without lung 
factor correction. The initial part delivered 
a dose of 40 Gy to a large volume 
including the supraclavicular areas with 
anterior and posterior fields, while the re-
maining 20 Gy were given using oblique 
or lateral fields limited to the bronchial 
stump, hilum and mediastinum. The treat-
ment required 4 or 5 sessions per week. 
The technique used (lateral fields, a large 
volume, a higher daily dose, a cobalt unit, 
absence of lung factor correction etc.) may 
easily explain the negative impact of irra-
diation and the higher non-cancer related 
death rate for daily doses above 2 Gy. 
   Postoperative irradiation for lung cancer 
represents a form of challenge for a ra-
diation oncologist: our aim is to prevent 
a locoregional relapse and to avoid 
inducing life threatening complications 
to different vital organs such as: the lung, 
the spinal cord and the heart. Further-
more, patients have already weakened 
their lung functions due to surgery and 
a long history of tobacco abuse. Large 
daily fractions and volumes, a high total 
dose and a poor radiation technique may 
account for the negative results observed 
in the metaanalysis. Any extension of mar-
gins or volumes of elective nodal irra-
diation will increase the amount of the nor-
mal tissue irradiated, especially the eso-
phagus and the normal lungs. The dose 
volume histogram analysis (DVH) has 
indicated a relation between the volume 
of the normal lung receiving doses in ex-
cess of 20 Gy and the risk of subsequent 
radiation induced pneumonitis. In the ex-
perience of Graham et al dealing with 
inoperable lung cancer, no case of grade 
3 pneumonitis was seen when less than 
25% of the lung received more than 
20 Gy; this rate was 23% when the volume 
was greater than 40% [18]. In our own 
experience, the quality of the radiation 
procedure was a key factor. All patients 
treated after pneumonectomy between 
1970 and 1985 were reviewed. Three 
groups were investigated: a control sur-
gical group only operated on for an early 
stage I tumour, a group of patients treated 
with a three-field technique and a Co60 
source, and a group of patients treated 
with a linear accelerator after treatment 
planning based on a postoperative CT. 
The dose delivered to the mediastinum 
was 56 Gy in daily fractions of 2 Gy. 
The 5-year survival rates were 4% 
for patients treated with Co60, and 30% 
for the surgical and the linac groups [19]. 
The latter groups included only stage 
III disease.  
   Postoperative irradiation of lung cancer 
is a very good model for 3D conformal 
radiotherapy. Schraube et al. have already 
shown that this technique made it possible 
to reduce the dose to the lung and 
the heart, while keeping the same total 
dose to the target area [20]. At the Uni-
versity of Giessen, 115 patients had a 3-D 
planned postoperative radiotherapy 
delivering a dose of 50 to 60 Gy whereas 
437 patients had only surgical resection: 
the radiation course made it possible 
to reduce the risks of death in patients with 
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nodal metastases without increasing 
the risk of late damage [21]. Using 
a modern radiation technique, Mornex 
et al. were able to deliver doses between 
50 and 55 Gy without impairing the patient 
lung functions [22]. 
   The aim of postoperative irradiation 
is to increase survival by virtue of reducing 
the locoregional relapse risk; the pattern 
of failure analysis should help to select 
patients for such a treatment. Data from 
surgical series reported about 10% of local 
relapse for stage I disease (Table 2) 
[9,12,14,15,17,23-28]. In our own rando-
mized trials, including only T1T2No tumour 
operated on by the same surgical team, 
the rates of «in field» local failures were 
13% after surgery alone and 8% after 
postoperative irradiation respectively. 
Clearly, routine postoperative irradiation 
appears not to be indicated for stage 
I tumour after complete resection. 
In a recent trial including 104 patients with 
a pathological stage I non-small cell lung 
cancer, postoperative irradiation was 
restricted to the area of the bronchial 
resection and the hilum, and a dose 
of 50 Gy was delivered. This treatment 
reduced the number of locoregional 
relapse from: 1 out of 51 vs. 12 out 53 
for surgery only [17]. The figure of 22.5% 
of local failure is very high as compared 
with many other surgical series. In con-
trast, local failure seems to be a more 
common problem in more advanced 
tumours, with failure figures ranging 
between 20 and 40%. In four large trials, 
a trend was observed for an improved 
local control after postoperative irradiation 
[12,13,14,16]. In the Lung Cancer Study 
Group trial, only one case of local failure 
was noted among 102 patients receiving 
postoperative irradiation in contrast 
to 21 out of 108 patients for the surgical 
arm only [13]. In the Feng trial, local failure 
within the chest dropped from 40% to 16% 
after postoperative irradiation for stage 
III disease [12]. In a review of controlled 
and retrospective studies of patients only 
those undergoing surgery or receiving 
additional postoperative irradiation 
for stage II and III disease, the rate 
of locoregional failure varied from 
12 to 60% after surgery, and from 
1 to 45% after postoperative radiotherapy 
(Table 3). The average local relapse rate 
was about 30% after surgery alone and 
13% after postoperative radiotherapy 
[13,14,24,26,29-36]. Postoperative radio-
therapy appears to improve local control 
but the survival benefit is not known. 
 
Table 2. Pattern of failure after surgery for lung cancer. 
Authors Tumor Stage Number of patients Local failure 
(%) 
Martini T1-T2 N0 110 0 
Immerman T1-T2 N0 77  12 
Van Houtte T1-T2 N0 78 13 
Pairolero T1N0 
T2N0 
170 
158 
6 
6 
Feld T1N0 
T2N0 
162 
195 
9 
11 
Granone T1-T2 N0 53 22.5 
Laffite T2N0 70 14 
Sawyer T1-T2 N0 370 15 
Lung Cancer Study Group N1-N2 108 20 
Stephens T1-T2 N1 
T1-T2 N2 
91 
54 
49 
41 
Feng Stage II 
Stage III 
82 
80 
29 
37 
Immerman T1-T2 N1 22 41 
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   At present, there is a general trend in 
favor of a neoadjuvant approach with 
chemotherapy, or a combined approach. 
This will raise a new series of questions: 
should postoperative irradiation be limited 
to incomplete resection for residual N2 
disease, or should we decide about our 
treatment on the initial tumour extension? 
Several other questions remain unans-
wered: should the type of mediastinal 
resection be taken into account? What is 
the role of nodal capsular rupture, a well-
known poor prognostic factor for head 
and neck cancers? What is the role 
of the histological type? In addition 
to the role of chest irradiation, brain 
failures present a common problem in ma-
ny series questioning the role of prophy-
lactic irradiation. However this issue has 
never been addressed in a well-conducted 
randomized trial. 
 
 
Table 3. Local relapse after surgery with or without postoperative radiotherapy for locally advanced lung cancer. 
                                                                           
  SURGERY  POSTOP. RADIOTH. 
Authors N Loc. Rel. (%) N Loc. Rel. (%) 
Choi 32 53 41 31 
Chung 29 48 38 8 
Van Houtte   142 9 
Emami   69 11 
Lung Cancer Study Group 108 20 102 1 
Ludwig Lung Cancer Study G. 253 30   
Immerman 22 41   
Durci 41 36 38 45 
Herskovic   64 19 
Astudillo 60 12 71 19 
Baillet    203 34 
Feng 162 33 134 13 
Keller   242 13 
Stephens 154 47 154 37 
 
CONCLUSIONS 
 
   Surgery still remains the corner stone 
in the treatment of non-small cell lung 
cancer. The place of adjuvant treatment, 
either chemotherapy or radiotherapy, 
remains unclear. The possible benefits 
in terms of survival are probably very low, 
but due to the great number of patients 
suffering from this disease, this is a very 
important issue. Postoperative radio-
therapy improves the locoregional control 
for stage III disease, but requires a very 
precise technique. More studies are still 
needed to answer many of the remaining 
questions. 
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